Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Issued: June 21, 2023
Subject: Announcement of positive clinical data for Arexvy, GSK's respiratory syncytial virus (RSV) vaccine for older adults, derived from the ongoing AReSVi-006 Phase III trial.
Key Financial Metrics
This filing is a clinical data announcement and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details new efficacy data for Arexvy over two RSV seasons in adults aged 60 and older:
- Single Dose Efficacy (Season 1): 82.6% against RSV-lower respiratory tract disease (LRTD); 94.1% against severe LRTD.
- Single Dose Efficacy (Season 2): 77.3% against RSV-LRTD; 84.6% against severe LRTD.
- Cumulative Efficacy (Two Seasons): 67.2% against RSV-LRTD; 78.8% against severe LRTD.
- Revaccination: Cumulative efficacy with a second dose was 67.1%, suggesting annual revaccination does not currently appear to confer additional benefit for the overall population.
- Safety: Data consistent with initial Phase III results; generally well tolerated with mild to moderate transient adverse events (e.g., injection site pain, fatigue).
Outlook, Management Commentary, and Risks
Management Commentary: Tony Wood, Chief Scientific Officer, stated the data reinforces confidence in the vaccine's potential public health impact, particularly for those at high risk due to age or underlying conditions. GSK plans to discuss results with regulators and vaccine recommending bodies.
Regulatory Status:
- US: Approved by FDA on May 3, 2023.
- Europe: Authorized by European Commission in June 2023.
- Other: Reviews ongoing in Japan and other countries.
Next Steps: Data will be presented at the CDC's ACIP meeting on June 21, 2023, and submitted to the FDA and other regulators. The clinical program will continue to evaluate longer-term follow-up and optimal revaccination timing.
Risks: Forward-looking statements are subject to risks and uncertainties, including those described in the 2022 Form 20-F and Q1 2023 results, as well as potential impacts from the COVID-19 pandemic.
Key Facts for Investor Verification
- Verify the commercial launch timeline and sales projections for Arexvy following FDA and European Commission approvals.
- Monitor the outcome of the CDC ACIP meeting regarding vaccination recommendations for older adults.
- Track regulatory approval status in Japan and other key international markets.
- Review future clinical data regarding the optimal timing for potential revaccination.
- Assess the competitive landscape for RSV vaccines in the older adult demographic.